KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - AccuredReceivables - NetRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Arbutus Biopharma (ABUS) Other Non-Current Liabilities (2016 - 2025)

Historic Other Non-Current Liabilities for Arbutus Biopharma (ABUS) over the last 15 years, with Q3 2025 value amounting to $11.1 million.

  • Arbutus Biopharma's Other Non-Current Liabilities rose 3317.34% to $11.1 million in Q3 2025 from the same period last year, while for Sep 2025 it was $11.1 million, marking a year-over-year increase of 3317.34%. This contributed to the annual value of $10.2 million for FY2024, which is 3453.95% up from last year.
  • Latest data reveals that Arbutus Biopharma reported Other Non-Current Liabilities of $11.1 million as of Q3 2025, which was up 3317.34% from $10.8 million recorded in Q2 2025.
  • In the past 5 years, Arbutus Biopharma's Other Non-Current Liabilities registered a high of $19.4 million during Q1 2021, and its lowest value of $7.6 million during Q4 2023.
  • Moreover, its 5-year median value for Other Non-Current Liabilities was $10.5 million (2025), whereas its average is $11.9 million.
  • In the last 5 years, Arbutus Biopharma's Other Non-Current Liabilities tumbled by 3921.89% in 2023 and then soared by 3500.0% in 2025.
  • Over the past 5 years, Arbutus Biopharma's Other Non-Current Liabilities (Quarter) stood at $16.3 million in 2021, then tumbled by 36.4% to $10.4 million in 2022, then dropped by 26.68% to $7.6 million in 2023, then surged by 34.54% to $10.2 million in 2024, then grew by 8.56% to $11.1 million in 2025.
  • Its last three reported values are $11.1 million in Q3 2025, $10.8 million for Q2 2025, and $10.5 million during Q1 2025.